Kurtz Ronald M MD's Form 4 filing
RxSight, Inc. (RXST) · filed Jan 9, 2024
- Accession no.
- 0000950170-24-003332
- Filed
- Jan 9, 2024
- Trade date
- Jan 8, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.77M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kurtz Ronald M MDCIK 0001295469 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2024 | Common Stock | SSaleDisposed | −31,250 | $43.50 | −$1,359,375 | 835,860 | Indirect | |
| Jan 8, 2024 | Common Stock | SSaleDisposed | −31,250 | $45.00F3 | −$1,406,250 | 804,610 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average share price of an aggregate total of 31,250 shares sold in the price range of $45.00 to $45.02 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.